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On April 23, 1951, a 30-year-old woman received the first intentional ABOi (ABO 
incompatible) renal transplantation in Boston. At that time, it was commonly believed 
that intensely rinsing the graft to remove blood would be sufficient to overcome any 
immunological problems associated with blood type incompatibility. However, when the 
abovementioned patient and another ABOi transplant recipient died within a month, 
Humes and colleagues arrived at the same conclusion: “We do not feel that renal 
transplantation in the presence of blood incompatibility is wise.” In the decades that 
followed, we learned that the oligosaccharide surface antigens representing the ABO- 
blood group antigens are expressed not only on erythrocytes but also on cells from various 
tissues, including the vascular endothelium. The growing gap between organ demand 
and availability has sparked efforts to overcome the ABO barrier. After its disappointing 
results in the early 1970s, Japan became the leader of this endeavor in the 1980s. All 
protocols are based on 2 strategies: removal of preformed antibodies with extracorporeal 
techniques and inhibition of ongoing antibody production. Successful ABOi renal 
transplantation became possible with the advent of splenectomy, new immuno-
suppressive drugs (e.g., rituximab, a monoclonal antibody against CD20), and extra-
corporeal methods such as antigen-specific immunoadsorption. This review summarizes 
the underlying pathophysiology of ABOi transplantation and the different protocols 
available. Further, we briefly touch potential short- and long-term problems, particularly 
the incidence of infectious complications and malignancies, that can arise with 
high-intensity immunosuppressive therapy.
Key Words Graft survival, Graft loss, Rejection, Preconditioning
Correspondence to
Jan T. Kielstein, M.D., Ph.D.
Department of Internal Medicine, Division 
of Nephrology and Hypertension Medical 





Ⓒ2011 Korean Society of Hematology
INTRODUCTION
1. Mind the gap
The optimal treatment for most patients with chronic 
kidney disease stage 5/5D is successful renal transplantation, 
which, compared to dialysis, results in significantly lower 
mortality and morbidity rates. Despite intensive efforts pro-
moting postmortem organ donation and the change in legis-
lation that regulates organ donation in some countries, there 
is an ever-increasing organ shortage worldwide. Thus, this 
treatment is becoming increasingly difficult to implement. 
A s  a  r e s u l t ,  n e a r l y  1 0 %  o f  p a t i e n t s  i n  t h e  E u r o p e a n  
Community die while awaiting a suitable graft. Because of 
the shortage of donor organs, the number of transplantations 
involving living organ donors who are related to the patient 
is increasing steadily. However, about 20% of eligible living 
kidney donors are blood-group incompatible. Since blood 
group antigens are considered the most antigenic in the 
transplantation process, there is a high risk of hyperacute 
transplant rejection mediated by preformed blood groups 
antibodies.
2. The ABO system
The ABO system was introduced by the Austrian scientist 
Karl Landsteiner in 1900 [1]. The blood group designation 
is dependent on the presence or absence of A and B antigens 
on the surface of the red blood cells. ABO blood group 
antigens are oligosaccharide surface antigens expressed on 
erythrocytes, tissue cells, and in saliva and other body fluids. 
All blood group antigens contain the H-antigen as a common 
precursor. Expression of the A- or B-allele-encoded glycosyl-
transferase catalyzes the addition of specific carbohydrate 
determinants to the H-antigen. The H-antigen is the only 
ABO structure present in blood type O; expression of the 
O allele induces no functional glycosyltransferase [2]. The Korean J Hematol 2011;46:164-8.
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Fig. 1. Hyperacute rejection mediated by ABO antibodies. Preformed 
natural antibodies bind to blood group carbohydrate structures on 
endothelial cells. This leads to complement fixation, microthrombosis
and microhemorrhages.
ABO subgroups are determined by the density of A-, B-, 
or O (H)-antigen expression on the surface of red blood 
cells. A1 is the most frequent A subtype in Europe; it has 
a surface expression of 1,000,000 antigens per red blood 
cell. A1 has the highest expression rate and is distinguished 
from A2, A3, Ax, Aend, Am and Ae1 subtypes, which are sig-
nificantly lower in antigenic surface expression [3, 4]. 
Similarly, the antigen density determines the B subtypes 
as well. The B subtype with the highest surface expression 
is type B, which has 700,000 antigens expressed on the surface 
of each red blood cell. B3, Bx, Bm and Be1 express lower 
amounts of antigen on the surface [5]. Using the same system, 
AB can be subclassified into 9 different subtypes. Interest-
ingly, serum antibodies are specific for other blood types. 
Blood type O contains antibodies against A and B; blood 
type A contains antibodies against B and vice versa; and 
blood type AB expresses both antigens but no antibodies. 
Interestingly, these antibodies are not present in newborns, 
but develop during the first year of life, presumably in re-
sponse to food and environmental antigens [6]. The presence 
of preformed antibodies and the expression of blood group 
antigens on blood vessel endothelia are the basis for the 
initial paradigm that organ transplantation across blood 
group barriers is impossible.
3. Preformed antibodies and hyperacute rejection
Without preconditioning, transplantation across the ABO 
barrier will lead to hyperacute rejection within minutes (Fig. 
1). The recipient’s preformed “natural antibodies” react with 
the ABO carbohydrate antigens expressed on the vascular 
endothelial cells in the graft. Antibody binding leads to fix-
ation and activation of complement, which induces endothe-
lial cell activation and damage, and finally results in the 
formation of microthrombi and microhemorrhages (Fig. 1). 
The origin and function of “natural antibodies” remain ob-
scure; they are produced without prior antigen exposure 
by a subset of B-cells expressing CD5 (CD5-negative B-cells 
are responsible for antigen-induced antibody production) 
[7]. In addition to the preformed antibody response, maxi-
mized immune activation occurs against the graft; the blood 
group antigens are considered the most antigenic in the 
transplantation process [8]. Therefore, patients require pre-
conditioning to remove natural antibodies and to buffer the 
initial immune response until “graft-accommodation” has 
occurred (see below).
4. Role of the von Willebrand factor
vWF (von Willebrand factor) is a large plasma glycoprotein 
synthesized by endothelial cells and megakaryocytes, and 
it has a key role in the initial phase of hemostasis [9]. vWF 
is continuously secreted into the plasma and is stored in 
endothelial Weibel-Palade bodies or in the alpha-granules 
of platelets. Interestingly, vWF mediates platelet adhesion 
to the site of damage, and one of its unique features is to 
facilitate the covalent linking of ABO antigens to the sugar 
chain [10]. This sort of glycosylation is also mediated by 
glycosyltransferase activity in the endothelial cells. The exact 
biological function of ABO antigens on vWF and the influ-
ence of vWF on hemostasis or thrombotic complications 
is still unclear. However, it is known that persons with 
blood type O have a significantly lower vWF concentration. 
Interestingly, studies in patients who had received an ABO- 
mismatched bone marrow transplantation have revealed that 
the majority of glycosylated vWF is synthesized in the renal 
endothelium. vWF molecules derived from the renal endo-
thelium expressed blood group antigens, whereas vWF mole-
cules derived from platelets did not. Therefore, vWF glyco-
sylation plays a role in increased presentation of donor-ABO 
antigens in the recipient as well, and it may be associated 
with the development of immunological tolerance in recipi-
ent plasma [11].
TREATMENT PROTOCOLS FOR ABO-INCOMPATIBLE 
TRANSPLANTATION-FROM NORMAL SALINE FLUSH 
TO ANTIGEN-SPECIFIC IMMUNOADSORPTION
1. The pioneers of ABO-incompatible renal transplantation
On April 23, 1951, a 30-year-old woman received the 
first intentional ABOi (ABO incompatible) renal trans-
plantation in Boston. Hume and colleagues [12] wrote in 
their seminal paper: “The donor’s blood type was O, Rh +, 
while that of the recipient was A, Rh +, thus presenting 
compatibility in the major grouping but not in the minor.” 
Based on the pathophysiological knowledge available at that Korean J Hematol 2011;46:164-8.
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time, the pioneers of renal transplantation believed that the 
graft would be made acceptable by simply perfusing the 
graft intensely with normal saline. However, the graft in-
fracted early in the process and never gained function. They 
sensed that the problem may have been related to blood 
type incompatibility in the graft, and thus, for the second 
intentional ABOi renal transplantation (performed on May 
7, 1952), the graft was “perfused with 500 mL of Ringer’s 
solution to which 25 g of albumin and 200,000 units of 
penicillin had been added.” Both recipients died 25 and 19 
days after the surgery. The authors arrived at the following 
conclusion: “We do not feel that renal transplantation in 
the presence of blood incompatibility is wise” [12]. In the 
years that followed, several reports documented accidental 
ABOi transplantations that led to rapid graft loss within 
the first year after transplantation [13, 14]. A report on 
the first successful series of 26 patients was published by 
Alexandre and coworkers [15]; the treatment protocol in-
cluded a simultaneously performed splenectomy. Later, this 
protocol was adopted by Japan, the country with the most 
experience in this area, and 851 ABOi transplantations were 
conducted in 82 centers between 1989 and 2005 [16].
All 3 of the major protocols (from Japan, USA, and Europe) 
are based on 2 strategies: removal of preformed antibodies 
by extracorporeal techniques and inhibition of antibody 
production.
2. Removal of preformed antibodies
The circulating antibodies produced against ABO antigens 
that are not present in the recipient will cause antibody- 
mediated rejection of the graft, and hence, these antibodies 
have to be removed prior to the transplantation. The anti-
bodies can be removed by either specific or non-specific 
extracorporeal treatment methods.
Bier and colleagues have conducted important preclinical 
studies since the early 1970s; these studies had paved the 
road to the clinical application of therapeutic plasma ex-
change (TPE) [17]. They demonstrated the ability of TPE 
to selectively reduce the circulating antibody and to sig-
nificantly delay the rejection of porcine kidney xenografts 
in dogs. A decade later, Bensinger et al. showed that TPE 
(or immunoadsorption) could be used to remove ABO anti-
bodies, thus allowing successful ABOi bone marrow trans-
plantation [18]. This technique also was used to rescue the 
graft of a patient who had mistakenly received an ABOi 
kidney [19]. Interestingly, TPE not only reversed the acute 
rejection in this patient but also reduced the damage to 
such a degree that long-term (20 months) graft function 
was normal. These publications were critical to the decision 
of Alexandre and coworkers [15] to employ TPE as an essen-
tial tool for removing antibodies prior to initiating an ABOi 
transplantation; it is still the method of choice in Japan 
and the USA [20-22]. A variation on the theme of TPE 
is DFPP (double-filtration plasmapheresis). In DFPP, plasma 
is separated using a plasma separator, in which plasma passes 
through a plasma component separator (small pores). Large 
molecular weight proteins are discarded, and the small mo-
lecular weight substances, including albumin, are cycled back 
to the patient. Compared to standard TPE, this approach 
reduces the volume of replacement fluid required, i.e., albu-
min [23].
A more specific method for removing isoagglutinins is 
IA (immunoadsorption). In the early 1980s, a solid-phase 
immunoadsorbent column with blood group A trisaccharide 
had been used to demonstrate the specific removal of anti-A 
antibody from human plasma in vitro; moreover, dogs immu-
nized in vivo displayed no toxicity [24, 25]. The Glycosorb 
ABO column, a single-use column that efficiently reduces 
donor-specific anti-A and anti-B IgM and IgG by 81% and 
56%, respectively, at the first treatment [26], is currently 
used in all published European protocols [27-29]. Some au-
thors believe that antigen-unspecific immunoadsorption by 
the Globaffin or Ig-Therasorb device is equivalent in efficacy 
to antigen-specific immunoadsorption, despite the absence 
of comparative studies [30].
3. The Japan protocol
Because of the decreasing number of deceased organ do-
nors, Japan had started a program on ABOi transplantation 
in 1989. In this program, the natural antibodies are pre-
operatively removed by DPFF, and the kidney trans-
plantation is combined with a splenectomy in addition to 
immunosuppressive therapy with CNIs, anti-metabolites, 
and steroids. This protocol resulted in graft survival that 
was comparable to the survival outcomes following ABO- 
compatible transplantation [16]. One of the major dis-
advantages of this protocol is the high rate of infection and 
postoperative complications that are associated with splenec-
tomy, such as postsplenectomy septic syndrome, atelectasis, 
pancreatitis/fistula, pulmonary embolism, and bleeding at 
the operative site [31]. Therefore, instead of performing a 
splenectomy, many institutions now use anti-CD20 antibody 
(rituximab), which markedly reduces the incidence of acute 
antibody-mediated rejection [21].
4. The Johns Hopkins protocol
The Johns Hopkins (USA) protocol is based on rituximab 
and TPE. Depending on the pretransplant antibody titer, 
2-15 TPEs are performed preoperatively [32] and is followed 
by low-dose CMV hyperimmunoglobulin and rituximab 
(formerly splenectomy). The patient and graft survival rates 
in ABOi transplantation are comparable to national statistics 
for compatible live donor transplants [33].
5. The Stockholm protocol
Tyden and coworkers developed a novel protocol in 2003 
[28]. Preoperative B-cell ablation therapy is performed using 
anti-CD20 antibodies (375 mg/m
2), and the TPE component 
is replaced by a more specific approach for removing the 
preformed natural antibodies by using specific anti-A or 
anti-B directed IA. In addition, the recipient receives a com-
bination of immunosuppressants with mycophenolate, tacro-
limus, and steroids for 10 days before the planned trans-
plantation.Korean J Hematol 2011;46:164-8.
ABO-incompatible renal transplantation 167
6. The Hannover protocol
In Hannover, the Tyden-Protocol is used with minor 
modifications. The patients receive an anti-CD20 treatment 
4 weeks before the planned transplantation, and they begin 
immunosuppressive therapy with tacrolimus (trough level, 
8 ng/mL) combined with mycophenolate (2×0.5 g/d) and 
steroids (0.3 mg/kg). One week before the planned trans-
plantation, daily IA is conducted using Glycosorb columns 
selected to fit the anti-erythrocyte antibody constellation 
until the isoagglutinin titer is at or below 1：8. The day 
before transplantation, the patients receive 30 g im-
munoglobulins i.v. (intravenously), and 500 mg of a steroid 
is administered i.v. during transplantation. The mycopheno-
late dosage is increased to 2×1 g/d. The tacrolimus dosage 
is adapted to reach trough levels-12 ng/mL for up to 4 weeks 
and 10 ng/mL for up to 3 months, with further reduction 
as usual and according to the clinical situation. Steroids are 
tapered as is typical after kidney transplantation. Recently, 
routine IA after transplantation was switched to an on de-
mand approach. IA is continued throughout the first 2 weeks, 
if the titer is higher than 1：8 during the first week and 
higher than 1：16 during the second week. Regular addi-
tional application of anti-interleukin-2 antibody on days 1 
and 4 after transplantation were discontinued since a higher 
rate of infection was observed for that combination. Higher 
rejection rates were not experienced after the anti-inter-
leukin-2 antibody was removed from the treatment regimen.
ACCOMMODATION
The most critical phase after ABOi transplantation is the 
early postoperative phase. The risk for developing an acute 
rejection related to blood group antigens is low after the 
initial phase despite the fact that blood group-specific anti-
bodies are produced continuously by the recipient. This type 
of tolerance is referred to as “accommodation,” and its under-
lying mechanisms are poorly understood. One explanation 
might be the presence of a defective glycosyltransferase, 
an enzyme that facilitates blood group antigen synthesis 
in the donor organ. The ischemia and reperfusion injury 
of the donor organ leads to inactivation of this enzyme; 
therefore, the donor endothelium expresses fewer blood 
group antigens, which leads to reduced immunogenicity [34].
The activity of the glycosyltransferase is lost and the blood 
group antigens lose their immunogenicity within 2 weeks 
after transplantation and after the initial functional recovery, 
but the antigens are still present. The second paradox involves 
positive C4d complement in the peritubular capillaries, 
which is one of the hallmarks of antibody-mediated rejection 
according to the Banff Classification; however, this occur-
rence in ABOi transplantation is not associated with a higher 
rejection rate. A recent study on protocol biopsies that com-
pared ABO-compatible and ABOi renal transplants revealed 
C4d positivity in 94% of the ABOi cases (N=89 biopsies 
of 45 patients), with other signs of rejection occurring in 
less than 50% of those cases; however, 11% C4d positivity 
was detected in the compatible cases (N=250), which were 
all associated with graft rejection [35].
The success in ABOi renal transplantation has even en-
couraged physicians to perform intentional ABOi liver trans-
plantation [36, 37]. Using a pre-, peri-, and postoperative 
antibody depletion protocol, which included TPE, i.v. Ig 
administration, rituximab therapy, and IA, we also performed 
the first successful ABOi lung transplantation at the Medical 
School, Hannover [38].
1. Potential side effects
The high intensity of immunosuppression increases the 
risk for both infections and neoplasms. Interestingly, the 
use of Glycorex antigen-specific immunoadsorption is asso-
ciated with the removal of antibodies against Pneumococcus 
and Haemophilus polysaccharide antigens, but anti-tetanus 
and anti-diphtheria protein antibodies are not affected [39]. 
Nevertheless, after more than 3 years, outcome data indicate 
that ABOi kidney transplantation does not differ from 
ABO-compatible transplants [29, 40]. More recent data from 
Hannover indicate that intense immunosuppression might 
lead to a significant increase in viral infections [27].
In summary, ABOi living-donor kidney transplantation 
represents an accepted therapeutic procedure for long-term 
graft survival, which is comparable to that in ABO-compat-
ible living kidney donations. Thus far, the risk of infection 
and neoplasm linked to immunological preconditioning with 
modern immunosuppressive drugs and specific or non-specif-
ic elimination of preformed antibodies seem to fall within 
acceptable limits; however, long-term data are necessary 
to confirm this. More sophisticated monitoring of immune 
function may be helpful for developing tailor-made im-
munosuppression regimens, particularly for this patient 
population.
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